发明公开
- 专利标题: ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
- 专利标题(中): 作者AMP ZESTE-同源-2抑制剂
-
申请号: EP13870106.5申请日: 2013-12-12
-
公开(公告)号: EP2931707A1公开(公告)日: 2015-10-21
- 发明人: KNIGHT, Steven, David , MILLER, William, Henry , NEWLANDER, Kenneth, Allen , DONATELLI, Carla, A.
- 申请人: Glaxosmithkline LLC
- 申请人地址: 2711 Centerville Road Suite 400 Wilmington New Castle, DE 19808 US
- 专利权人: Glaxosmithkline LLC
- 当前专利权人: Glaxosmithkline LLC
- 当前专利权人地址: 2711 Centerville Road Suite 400 Wilmington New Castle, DE 19808 US
- 代理机构: Reed, Michael Antony
- 优先权: US201261736645P 20121213; US201361777443P 20130312
- 国际公布: WO2014107277 20140710
- 主分类号: C07D213/56
- IPC分类号: C07D213/56
摘要:
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. Epigenetic modifications play an important role in the regulation of many cellular processes including cell proliferation, differentiation, and cell survival. Global epigenetic modifications are common in cancer, and include global changes in DNA and/or histone methylation, dysregulation of non-coding RNAs and nucleosome remodeling leading to aberrant activation or inactivation of oncogenes, tumor suppressors and signaling pathways.
信息查询